| http://www.w3.org/ns/prov#value | - BEVERLY, MA--(Marketwire - April 01, 2013) - Cellceutix Corporation (OTCBB: CTIX) (the Company), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces that the Company's abstract on Kevetrin???, Cellceutix's flagship cancer drug candidate in clinical trials at D
|
